Loading…
← CockpitCompetitor Analysis › 009420.KS Hanall BiopharmaOpen in the cockpit ↗

Hanall Biopharma009420.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major

Korean biopharma developing autoimmune and eye-disease antibody drugs, including an FcRn inhibitor licensed to global partners.

Momentum leader 91
Mkt cap
$2.01B
US dollars, full cap
Free float
66%
of shares outstanding
$/day
$9.22M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-5.5 pp
WACC 7.6%
Hurdle
n/a
no reverse DCF
Next earnings
63 days
20 Jan 2027
Close · KRW₩52,300
1D-2.4%
1W+5.3%
1M+25.9%
3M-12.4%
6M+12.5%
YTD+19.5%
1Y+10.4%
ATR %6.0%
52w lowhigh28.4% off high

What Hanall Biopharma does

Korean biopharma developing autoimmune and eye-disease antibody drugs, including an FcRn inhibitor licensed to global partners.

Partners Immunovant and Harbour BioMed, not Hanall, run the late-stage trials for batoclimab, so Hanall relies on upfront payments, milestones and royalties from them while its Korean branded-generic drugs pay current costs.

Products and services

  • Batoclimab (FcRn inhibitor)
  • Ophthalmology drug pipeline
  • Branded generic drugs

Customers

  • Global pharma licensing partners (Harbour BioMed/I

Where it sits in the supply chain

  • Biotechnology
  • Autoimmune/ophthalmology antibody drugs
  • Global pharma licensing

What could go right

  • Batoclimab global approval/launch via partners
  • Milestone/royalty payments

What could go wrong

  • Clinical-trial/regulatory risk
  • Reliance on partner licensing milestones

Moat: narrow (IP / patents). Licensed FcRn-inhibitor antibody drug now in global late-stage trials via partners.

Headquarters: Seoul, South Korea · Founded: 1973 · Employees: 315

Named competitors

  • argenx ARGX
  • UCB private or unlisted

Hanall Biopharma at a glance

Size Hanall Biopharma (009420.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $2.01B, the 140th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩52,300 on 18 Nov 2026.

Performance Over six months the shares gained 12.5%, against -5.5% for the median peer and -37.2% for the South Korea market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 5.0% over the last twelve months (peer median +11.1%); the operating margin is 3.0% (peer median 22.2%).

Valuation It trades at 16.6× enterprise value to sales against a peer median of 4.8× (2nd most expensive of 20).

Capital Return on invested capital runs 5.5 points below its cost of capital (7.6% WACC).

Next results Next results expected around 20 Jan 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026009420.KS 113Peer median 93
Six months, rebased to 100: Hanall Biopharma against the median of its 20 peers (local-currency closes).

Hanall Biopharma financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩162B₩155B₩139B₩135B₩110B
Revenue growth—+12%+3%+23%—
Gross profit₩83.0B₩79.1B₩71.7B₩73.7B₩60.6B
EBITDA₩8.00B₩1.94B₩3.35B₩4.99B₩4.56B
Net income-₩22.1B-₩5.56B-₩1.80B₩3.51B₩251M
Free cash flow-₩7.82B-₩3.29B₩7.72B₩27.2B₩22.4B
Capital expenditure₩11.5B₩14.1B₩23.1B₩9.20B₩7.68B
Total debt₩39.9B₩31.9B₩1.45B₩1.29B₩1.31B

Quarterly statements and history in the cockpit →

Hanall Biopharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%9969300436603456603707ERIS600285BHVNONESOURCEHRMYH0260020145400512SHILPAMED214450ALIVUSPFIZER300009600211COHANCE009420.KS6-month return →1-month return →
Up and to the right = strong over both horizons. Hanall Biopharma is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×10×20×30×9969300436603456603707ERISONESOURCEHRMYH02600201SHILPAMED214450300009COHANCE009420.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hanall Biopharma is the large dot.

Hanall Biopharma competitors and peer comparison

Head to head with its named competitors (009420.KS vs ARGX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Hanall Biopharma 009420.KS$2.01B+12%+5%3%16.6×n/a
argenx SE Sponsored ADR ARGX$59.1B+17%+71%29%10.3×11.7%

How Hanall Biopharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hanall Biopharma against its 20 peers (data as of 18 Nov 2026)
Measure009420.KSPeer medianRank in peer set
1-month return+25.9%+0.3%highest of 21
6-month return+12.5%-5.5%5th highest of 21
Distance from 52-week high-28.4%-28.7%11th highest of 21
Revenue growth (TTM)+5.0%+11.1%6th lowest of 20
Operating margin3.0%22.2%3rd lowest of 20
EV / Sales16.6×4.8×2nd most expensive of 20
ROIC minus cost of capital-5.5 pp+1.6 pp4th lowest of 20
Net debt / EBITDA2.1×0.7×2nd most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%16.6×n/an/a
InnoCare Pharma 9969.HKHong Kong$2.01B-10%+146%35%2.8×-2.0%+341.1%
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%30.9×n/an/a
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%2.4×1.7%+15.7%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%3.2×5.1%+6.4%
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%6.2×26.3%+20.9%
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%3.3×-4.7%+10.6%
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%11.8×n/an/a
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%1.4×-10.5%+40.3%
Haw Par H02.SISingapore$2.08B-25%-13%30%8.4×3.2%+15.7%
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%7.3×23.4%-2.5%
Tsumura & 4540.TJapan$1.93B+6%+13%18%2.0×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%1.5×1.2%+14.1%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%10.1×n/an/a
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%4.0×-11.0%+37.6%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%6.3×20.1%+6.2%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%5.5×11.2%+2.4%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%4.8×8.0%+9.3%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%3.4×-1.2%+16.7%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%8.6×n/an/a

Questions

Who are Hanall Biopharma's main competitors?
Named competitors: argenx (ARGX), UCB (private or unlisted). The cockpit's measured peer set (industry) also includes InnoCare Pharma (9969.HK), Fujian Cosunter Pharmaceutical (300436.SZ), Zhejiang Jiuzhou Pharmaceutical (603456.SS), Nanjing King-friend Biochemical Pharmaceutical (603707.SS), Eris Lifesciences (ERIS.NS), Henan Lingrui Pharmaceutial (600285.SS).
Is Hanall Biopharma expensive compared with its peers?
On ev / sales it trades at 16.6× against a peer median of 4.8×, 2nd most expensive of 20 in its peer set.
How has Hanall Biopharma stock performed?
Over six months to 18 Nov 2026 the shares returned +12.5% against -5.5% for the median peer; over one year +10.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.